Armando S.
- Country
- Italy
- Department
- UO Oncologia medica e Ematologia
Research Overview
- A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Safety, Pharmacokinetics, and Efficacy of BAY 2416964 (AhR Inhibitor) and Pembrolizumab in Adults with Advanced Solid Tumors
- Evaluation of AMG 193 Combined with Additional Therapies in Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous MTAP-Deletion
Data & Insights
Has run more than one trial at 576 of 898 partner sites.
Specializations
Hematologic Oncology
Specializes in treating blood-based cancers and disorders with expertise in multiple myeloma, lymphomas, and leukemia. Works with novel therapeutic approaches including immunotherapy and targeted treatments.
- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Hodgkin's Lymphoma
- Myelofibrosis
Solid Tumor Oncology
Focuses on treating various types of solid tumors with particular interest in breast cancer, lung cancer, and melanoma. Implements innovative approaches using combination therapies.
- HER2-Positive Breast Cancer
- Small Cell Lung Cancer
- Pancreatic Adenocarcinoma
- Uveal Melanoma
Precision Medicine
Specializes in targeted therapies and biomarker-driven treatments, particularly focusing on specific genetic mutations and molecular profiles in cancer.
- KRAS/NRAS Wild-type Colorectal Cancer
- HER2-Negative Breast Cancer
- CLDN18.2 Positive Cancers
- Advanced Solid Tumors with KRASG12C Mutation
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.